===
EQS-News: Heidelberg Pharma AG / Key word(s): Half Year Report
Heidelberg Pharma Reports on First Half-Year 2024 and the Course of Business
2024-07-11 / 07:05 CET/CEST
The issuer is solely responsible for the content of this announcement.
PRESS RELEASE
Heidelberg Pharma Reports on First Half-Year 2024 and the Course of Business
. First preliminary efficacy data from the clinical trial with HDP-101 in multiple myeloma published

. Presentation of preclinical and clinical data of the proprietary ADC technology platforms at the AACR
Meeting 2024
. HDP-101 granted Orphan Drug Designation by the FDA
. Sale of a portion of future royalties for TLX250-CDx to HealthCare Royalty
. Professor Andreas Pahl takes over as Chief Executive Officer
Ladenburg, Germany, 11 July 2024 - Heidelberg Pharma AG (FSE: HPHA) published today its financial report on the first
six months of 2024 (1 December 2023 - 31 May 2024).
Professor Andreas Pahl, CEO of Heidelberg Pharma AG, commented: "We are very pleased with the positive preliminary
efficacy data from the Phase I clinical trial with our ATAC development candidate HDP-101. In three patients from the
fifth cohort, we saw an objective improvement in the disease ("partial remission"). One of these patients is currently
showing further improvement in the development of the disease.
For the second half of the year, we are focusing on patient recruitment and testing an optimized dosing regimen with
three arms in the sixth cohort. We are optimistic that our clinical trial will continue to develop positively, and that
the study participants will benefit from the therapy.
In March, we concluded an agreement with HealthCare Royalty on the partial sale of future royalties. The royalties
arise from the portfolio candidate TLX250-CDx that was out-licensed to Telix. This allows us to benefit now and in the
future from the success of the candidate, which could receive marketing authorization in the USA by the end of this
year."
Key events in the first six months of 2024
. HDP-101 (BCMA-ATAC) program: The first five patient cohorts and dose levels in the Phase I/IIa clinical
trial for the treatment of relapsed or refractory multiple myeloma have been completed. The first four patient
cohorts proved to be safe and well tolerated. In the fifth cohort, all patients at a dose of 100 µg/kg HDP-101
experienced a drop in thrombocyte count, which completely normalized after a few days and was clinically
unremarkable.
To mitigate this transient effect, the clinical team adjusted and optimized the medication regimen. Cohort 6 will
consist of three arms, with at least three patients enrolled in each arm. In consultation with the clinical
investigators, the dose will be 90 µg/kg in order to test these three dosing regimens with as little risk to the
patients as possible. Further cohorts are planned with the most promising dosing regimens from cohort 6 and an
increase in dose levels.
The relevant authorities approved the mentioned protocol adjustments, and the recruitment of the sixth cohort was
prepared. First patients are currently being screened.
Fortunately, in cohort 5, three of the five patients treated with 100 µg/kg showed biological efficacy and an
objective improvement in disease was detectable ("partial remission"). One of these patients is currently showing
further improvement in the development of the disease ("very good partial response"; VGPR).
. New preclinical data from the ATAC technology platform presented at the AACR 2024 Annual Meeting:
Heidelberg Pharma presented clinical and preclinical results of its ADC technologies at the American Association
for Cancer Research (AACR) Annual Meeting in April. Initial safety and preliminary efficacy data from the Phase I
clinical trial with the ATAC candidate HDP-101 were shown as well as preclinical data on the ATAC candidate
HDP-102.
In addition, scientists from Heidelberg Pharma presented the first preclinical data from the new HDP-201 project,
an exatecan-based ADC.
Following the conference, Heidelberg Pharma hosted its first R&D webinar with key opinion leaders (KOLs) in the ADC
field. In addition to presentations on the technology platform by the management team, preclinical data were
presented and interpreted by Rakesh Dixit, CEO of Bionavigen, Gaithersburg, USA, and clinical data from the study
with HDP-101 by Jonathan Kaufman, MD, Associate Professor of Hematology & Medical Oncology, Emory University School
of Medicine, Atlanta, USA.
. HDP-101 receives orphan drug designation from the FDA: At the end of March, Heidelberg Pharma announced
that the US Food and Drug Administration (FDA) had granted Orphan Drug Designation (ODD) to the ATAC candidate
HDP-101. Orphan Drug Designation is granted to a drug or biological product intended for the prevention, diagnosis
or treatment of rare diseases affecting fewer than 200,000 people in the United States. The status provides
significant incentives to encourage development of the drug.
. Agreement concluded on the partial sale of license fees to HealthCare Royalty: In early March 2024,
Heidelberg Pharma signed an agreement with HealthCare Royalty, Delaware, USA, (HCRx) for the sale of a portion of
future royalties from global sales of TLX250-CDx. Heidelberg Pharma received a non-refundable upfront payment of
USD 25 million and is also entitled to receive up to an additional USD 90 million from the sale of royalties if
defined milestones are reached. After HCRx has received a maximum cumulative amount, the royalties revert to
Heidelberg Pharma, and HCRx receives a low single-digit percentage of Heidelberg Pharma's royalties.
Partner Telix Pharmaceuticals Limited, a company based in Melbourne, Australia, (Telix) completed the submission of
the marketing authorization application for TLX250-CDx to the FDA in early June 2024 and expects to obtain
marketing authorization for the product by the end of 2024. An accelerated review ("priority review") was also
applied for in parallel.
. Change in the management: The Supervisory Board appointed Professor Andreas Pahl as the new Chief
Executive Officer effective 1 February 2024 after Dr. Jan Schmidt-Brand, long-standing Chief Executive Officer of
Heidelberg Pharma AG and Managing Director of the subsidiary Heidelberg Pharma Research GmbH, had stepped down on
31 January 2024 upon reaching retirement age.
Events after the reporting period
No significant events occurred after the end of the reporting period.
Financial results for the first six months of fiscal year 2024
The Heidelberg Pharma Group, which previously consisted of Heidelberg Pharma AG and its subsidiary Heidelberg Pharma
Research GmbH as of the reporting date, reports consolidated figures. Two new companies, HDP G250 AG & Co. KG and HDP
G250 Beteiligungs GmbH, were established as part of the HCRx agreement. These two companies are affiliated below the
parent company Heidelberg Pharma AG and are not operationally active.
The reporting period referred to below relates to the period from 1 December 2023 to the balance sheet date of 31 May
2024 (H1 2024).
The Heidelberg Pharma Group generated sales revenue and income of EUR 6.3 million in the first six months of the 2024
financial year (previous year: EUR 4.7 million), an increase of 34%.
Sales revenue amounted to EUR 4.1 million in both comparative periods and mainly comprised the group-wide cooperation
agreements for the ATAC technology (previous year: EUR 4.4 million).
At EUR 2.2 million, other income was significantly higher than the previous year's level of EUR 0.3 million and
consisted of government grants (EUR 1.1 million), the reversal of unutilized accrued liabilities (EUR 0.8 million) and
other items (EUR 0.3 million).
Operating expenses, including depreciation and amortization, amounted to EUR 15.6 million in the reporting period
(previous year: EUR 20.7 million).
The cost of sales was below the previous year's level, amounted to EUR 1.4 million (previous year: EUR 2.9 million) and
corresponded to 9% of operating expenses. Research and development costs of EUR 10.6 million fell in comparison to the
previous year (EUR 14.8 million) due to the less cost-intensive external production for the ATAC projects and the
ongoing clinical trial with HDP-101 compared to the same period in the previous year. At 68% of operating expenses,
this category continued to represent the largest cost block. Administrative expenses of EUR 3.0 million (previous year:
EUR 2.3 million) amounted to 19% of operating expenses. At EUR 0.6 million, other expenses for business development,
marketing and commercial market supply activities, which mainly comprise staff and travel costs, were slightly below
the previous year's level (EUR 0.7 million) and accounted for 4% of operating expenses.
The Heidelberg Pharma Group's net loss for the first six months of 2024 amounted to EUR 8.7 million (previous year:
EUR 16.0 million). The significant improvement is due to higher income and lower expenses. Earnings per share amounted
to EUR -0.19 and, taking into account the average number of shares, developed positively compared to the previous year
(EUR -0.34).
At the end of the 2024 reporting period, Heidelberg Pharma had cash of EUR 42.6 million, which was below the year-end
figure of EUR 43.4 million and the previous year's half-year figure as of 31 May 2023 (EUR 57.4 million). This means an
average monthly cash outflow of EUR 0.1 million for the first half of the 2024 financial year.
If the loan repayment in the amount of EUR 5 million is excluded, Heidelberg Pharma had an average cash inflow of EUR
0.7 million per month in the first six months of 2024, compared to an average cash outflow of EUR 3.2 million per month
in the prior-year period.
===
(MORE TO FOLLOW) Dow Jones Newswires

July 11, 2024 01:05 ET (05:05 GMT)